5 unchanged sentences
Patent Infringement Litigation
−Removed: In July 2020, we filed a complaint against Bruker Cellular Analysis (on October 3, 2023, PhenomeX, the successor to Berkeley Lights was acquired by Bruker Cellular Analysis), in the United States District Court for the District of Delaware, alleging that Bruker Cellular Analysis infringed and continues to infringe, directly and indirectly, the following patents exclusively licensed by the Company, including U.S.
−Removed: 10,421,936 and 10,704,018, by making, using, offering for sale, selling and/or importing Bruker Cellular Analysis’ Beacon Optofluidic System.
−Removed: In August 2020, we filed an additional related complaint against Bruker Cellular Analysis in the United States District Court for the District of Delaware, alleging that Bruker Cellular Analysis infringed and continues to infringe, directly and indirectly, U.S.
−Removed: 10,746,737 and 10,753,933.
−Removed: In September 2020, we filed another complaint against Bruker Cellular Analysis in the United States District Court for the District of Delaware, alleging that Bruker Cellular Analysis infringed and continues to infringe, directly and indirectly, U.S.
−Removed: 10,775,377 and 10,775,378.
−Removed: On December 3, 2020, the judge assigned to these three lawsuits ordered that they be transferred to the U.S.
−Removed: District Court for the Northern District of California.
−Removed: In these lawsuits, we are seeking, among other things, a judgment of infringement, a permanent injunction and damages (including lost profits, a reasonable royalty, reasonable costs and attorney’s fees and treble damages for willful infringement).
−Removed: In February 2021, these lawsuits were consolidated and assigned to the Honorable Judge Lucy Koh.
−Removed: In February 2021, Bruker Cellular Analysis filed a motion seeking leave to amend its counterclaims to add the allegations of unfair competition (as plead in the case described below) against AbCellera only.
−Removed: In July 2021, the Court allowed Bruker Cellular Analysis to amend its counterclaims to add the unfair competition claims subject to our right to seek dismissal with prejudice should the counterclaims not overcome objections previously presented by us to the court.
−Removed: The Company is continuing to oppose the unfounded counterclaim and we intend to seek dismissal with prejudice.
−Removed: In March 2021, the court set this matter down for a jury trial with a December 12, 2022 start date.
−Removed: In July 2021, Bruker Cellular Analysis filed a Petition for inter partes review of U.S.
−Removed: 10,087,408 that we exclusively license from the University of British Columbia.
−Removed: In July 2021, Bruker Cellular Analysis filed a second Petition for inter partes review of U.S.
−Removed: 10,421,936 that we exclusively license from the University of British Columbia.
−Removed: In August 2021, Bruker Cellular Analysis filed a third Petition for inter partes review of U.S.
−Removed: 10,738,270 that we exclusively license from the University of British Columbia.
−Removed: In August 2021, the court stayed the patent litigation against Bruker Cellular Analysis in view of the Petitions for inter partes Review filed by Bruker Cellular Analysis.
−Removed: In January 2022, the PTAB denied one petition and instituted one petition.
−Removed: In February 2022, the PTAB denied the final petition.
−Removed: Trial on the instituted petition occurred in November 2022.
−Removed: In January 2023, the PTAB issued its Final Written Decision with respect to our U.S.
−Removed: 10,087,408 rejecting all of Bruker Cellular Analysis’ grounds of unpatentability and determining that none of the challenged claims are unpatentable.
−Removed: Because the three aforementioned inter partes review matters have been resolved, we intend to seek relief from the Court to lift the pending stay and resume our patent infringement action against Bruker Cellular Analysis.
−Removed: On August 4, 2023, the District Court lifted the stay in the pending matter against Bruker Cellular Analysis.
−Removed: The case has since resumed.
−Removed: No trial date has been set.
−Removed: The Company maintains its belief in the merits of this infringement matter and will continue to enforce its intellectual property portfolio worldwide.
−Removed: On July 26, 2023, Bruker Cellular Analysis filed a Notice of Appeal in IPR2021-1249 matter.
−Removed: The appeal filed by Bruker regarding IPR2021-1249 to the United States Court of Appeals for the Federal Circuit is pending oral argument with a date to be scheduled.
−Removed: The Company believes the appeal is meritless and that the decision of the United States Patent Trial and Appeal Board will be upheld.
+Added: In July 2020, we filed a complaint against Bruker Cellular Analysis (on October 3, 2023, PhenomeX, the successor to Berkeley Lights was acquired by Bruker Cellular Analysis), in the United States District Court for the District of Delaware, alleging that Bruker Cellular Analysis infringed and continued to infringe, directly and indirectly certain patents.
+Added: In December 2025, the parties settled the case, resolving the patent infringement litigation.
+Added: As part of the settlement, Bruker Cellular Analysis will receive a license under the patents and Bruker Cellular Analysis will pay AbCellera an upfront payment as well as future royalty payments on sales of Bruker Cellular Analysis’ Beacon Optofluidic platform products worldwide through the life of the licensed patents.
Civil Lawsuit
7 unchanged sentences
The complaint seeks financial damages as well as other declarations.
−Removed: The Company filed a Notice of Application seeking to dismiss certain Company affiliates from the matter.
+Added: The Company has filed a Notice of Application seeking to dismiss certain Company affiliates from the matter.
No hearing date has been set.
2 unchanged sentences
No other activity is occurring with respect to this matter.
−Removed: The Company believes that Plaintiffs’ claim is meritless and frivolous in all respects and intends to defend itself appropriately.
+Added: The Company believes that Plaintiffs’ claim is meritless in all respects and intends to defend itself appropriately.
Mine Safety Disclosures.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.